CHA Bundang Medical Center said Thursday that it has signed a business agreement with CG Bio to co-develop a stem cell transporter based on 3D bio-printing.
|CHA Bundang Medical Center President and CEO Kim Jae-hwa (seated at left) and CG Bio CEO Yoo Hyung-seung pose for a photo after signing a cooperation agreement at CHA Bundang Medical Center in Seongnam, Gyeonggi Province, Wednesday.|
The two institutions plan to apply the 3D bio-printing stem cell technology to produce patient-tailored stem cell supports and use them in treating spinal cord injured patients.
They will make 3D stem cell support based on bio-printing, attract domestic and overseas research projects as well as discover, preserve and industrialize intellectual property while maintaining close cooperation with research and development, and exchanging information and researchers.
“We expect that the synergy between CHA Bundang Medical Center, which has strengths in stem cell research, and CG Bio, which has a strong foothold in research on 3D bio-printing, will create an innovative new medical technology,” CHA Bundang Medical Center President and CEO Kim Jae-hwa said. “Bundang Cha Hospital will continue to find and develop new medical technology and establish itself as a global research center.”
CG Bio CEO Yoo Hyung-seung also said, “Starting with this joint research, we will continue to innovate in the field of regenerative medicine based on 3D printing technology and grow into the world's leading regenerative medicine company.”
<© Korea Biomedical Review, All rights reserved.>